Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec;9(4):701-705.
doi: 10.1007/s40121-020-00338-x. Epub 2020 Sep 16.

Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All

Grant W Waterer  1   2 , Jordi Rello  3   4   5
Affiliations
Editorial

Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All

Grant W Waterer et al. Infect Dis Ther. 2020 Dec.

Abstract

COVID-19 is a new infectious disease causing severe respiratory failure and death for which optimal treatment is currently unclear. Many therapies have been proven to be ineffective; however, promising findings related to corticosteroid therapy have been published. Analysis of published data including in this issue suggests that therapy with corticosteroids in the range of 6 mg of dexamethasone (or equivalent) per day likely has a positive effect in patients requiring mechanical ventilation but there remains considerable doubt in patients over the age of 70, in patients with diabetes and patients with milder disease. Clinicians must consider the individual potential risks and benefits of corticosteroid in patients with COVID-19 rather than routinely using them until more data is available.

Keywords: ARDS; Coronavirus; Covid-19; Pneumonia; Precision medicine; RCT; SARS; Therapy.

PubMed Disclaimer

References

    1. Waterer GW, Rello J, Wunderink RG. COVID-19: first do no harm. Am J Respir Crit Care Med. 2020;201(11):1324–1325. doi: 10.1164/rccm.202004-1153ED. - DOI - PMC - PubMed
    1. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi: 10.1056/NEJMoa2001282. - DOI - PMC - PubMed
    1. Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383:517–25. - PMC - PubMed
    1. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020. 10.1056/NEJMoa2019014. - PMC - PubMed
    1. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382:2327–36. - PMC - PubMed

Publication types

LinkOut - more resources